Boothbay Fund Management’s Mineralys Therapeutics MLYS Stock Holding History

Boothbay Fund Management’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.1M	Buy	1,001,728 +9,646	+1%	+$283K	0.35%	23
2025 Q4	$36M	Buy	992,082 +49,456	+5%	+$1.98M	0.54%	17
2025 Q3	$35.7M	Buy	942,626 +125,700	+15%	+$2.72M	0.52%	19
2025 Q2	$11.1M	Sell	816,926 -106,477	-12%	-$1.54M	0.21%	106
2025 Q1	$14.7M	Buy	923,403 +273,380	+42%	+$3.14M	0.39%	33
2024 Q4	$8M	Buy	650,023 +44,067	+7%	+$576K	0.2%	144
2024 Q3	$7.34M	Buy	605,956 +181,773	+43%	+$2.2M	0.17%	154
2024 Q2	$4.96M	Buy	+424,183	New	+$5.34M	0.12%	230

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Boothbay Fund Management's MLYS Position: Q1 2026 in Review

Boothbay Fund Management increased its Mineralys Therapeutics (MLYS) stake by 0.97% in Q1 2026, buying an estimated $283K and bringing the position to 1,001,728 shares worth $27.1M. The position accounts for 0.35% of the portfolio, ranked #23.

Boothbay Fund Management first reported a position in MLYS in Q2 2024 and has held it in 8 quarters since. The position peaked at $36M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

Boothbay Fund Management held 1,001,728 shares of Mineralys Therapeutics worth $27.1M as of Q1 2026.
Boothbay Fund Management bought 9,646 Mineralys Therapeutics shares in Q1 2026, an estimated $283K.
Mineralys Therapeutics made up 0.35% of Boothbay Fund Management's portfolio in Q1 2026, its #23 holding.
Boothbay Fund Management first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 8 quarters since.
Boothbay Fund Management's Mineralys Therapeutics position peaked at $36M in Q4 2025.
214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.